Stereoselective metabolism of metoprolol in Caucasians and Nigerians ― relationship to debrisoquine oxidation phenotypeLENNARD, M. S; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1989, Vol 27, Num 5, pp 613-616, issn 0306-5251Article

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism ― hypothesis testingJACKSON, P. R; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1989, Vol 28, Num 6, pp 655-662, issn 0306-5251Article

Assessing the risks to human health associated with exposure to dioxinsWOODS, H. F.Process safety and environmental protection. 1995, Vol 73, Num 4, pp S32-S35, issn 0957-5820, SUPConference Paper

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism ― histograms and probit plotsJACKSON, P. R; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1989, Vol 28, Num 6, pp 647-653, issn 0306-5251Article

Inhibition of lignocaine metabolism by β-adrenoceptor antagonists in rat and human liver microsomesAL-ASADY, S. A. H; BLACK, G. L; LENNARD, M. S et al.Xenobiotica (London. Print). 1989, Vol 19, Num 9, pp 929-944, issn 0049-8254, 16 p.Article

The polymorphic oxidation of β-adrenoceptor antagonists: clinical pharmacokinetic considerationsLENNARD, M. S; TUCKER, G. T; WOODS, H. F et al.Clinical pharmacokinetics. 1986, Vol 11, Num 1, pp 1-17, issn 0312-5963Article

Assessment of an in situ rat intestine preparation with perfused vascular bed for studying the absorption and first-pass metabolism of drugsCASTLE, S. J; TUCKER, G. T; WOODS, H. F et al.Journal of pharmacological methods. 1985, Vol 14, Num 4, pp 255-274, issn 0160-5402Article

Clinical manifestations of carcinoid diseaseBAX, N. D. S; WOODS, H. F; BATCHELOR, A et al.World journal of surgery. 1996, Vol 20, Num 2, pp 142-146, issn 0364-2313Article

Funding the bridge to real transplantation : the national kidney foundation of Singapore modelWOODS, H. F; DURAI, T. T.Transplantation proceedings. 1992, Vol 24, Num 5, pp 2070-2072, issn 0041-1345Conference Paper

Backtracking booze with Bayes : the retrospective interpretation of blood alcohol dataJACKSON, P. R; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1991, Vol 31, Num 1, pp 55-63, issn 0306-5251, 9 p.Article

Histamine inhibition of mixed function oxidase activity in rat and human liver microsomes and in the isolated perfused rat liverMORRIS, C. Q; TUCKER, G. T; CREWE, H. K et al.Biochemical pharmacology. 1989, Vol 38, Num 16, pp 2639-2644, issn 0006-2952Article

Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in manBAX, N. D. S; JONES, R. W; LENNARD, M. S et al.British journal of clinical pharmacology. 1985, Vol 19, Num 5, pp 593-596, issn 0306-5251Article

Metoprolol metabolism and debrisoquine oxidation polymorphism―population and family studiesMCGOURTY, J. C; SILAS, J. H; LENNARD, M. S et al.British journal of clinical pharmacology. 1985, Vol 20, Num 6, pp 555-566, issn 0306-5251Article

Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's diseaseROSTAMI-HODJEGAN, A; LENNARD, M. S; WOODS, H. F et al.Pharmacogenetics (London). 1998, Vol 8, Num 3, pp 227-238, issn 0960-314XArticle

Omani experience with a heterogeneous group of kidney transplant recipients over a 10-year periodAGHANASHINIKAR, P. N; DAAR, A. S; MARHUBY, H et al.Transplantation proceedings. 1993, Vol 25, Num 3, pp 2359-2360, issn 0041-1345Conference Paper

Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeastELLIS, S. W; CHING, M. S; WATSON, P. F et al.Biochemical pharmacology. 1992, Vol 44, Num 4, pp 617-620, issn 0006-2952Article

The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiaeCHING, M. S; LENNARD, M. S; TUCKER, G. T et al.Biochemical pharmacology. 1991, Vol 42, Num 4, pp 753-758, issn 0006-2952Article

Propranolol oxidation by human liver microsomes-the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivityOTTON, S. V; GILLAM, A. M. J; LENNARD, M. S et al.British journal of clinical pharmacology. 1990, Vol 30, Num 5, pp 751-760, issn 0306-5251, 10 p.Article

Timolol metabolism and debrisoquine oxidation polymorphism: a population studyLENNARD, M. S; LEWIS, R. V; BRAWN, L. A et al.British journal of clinical pharmacology. 1989, Vol 27, Num 4, pp 429-434, issn 0306-5251Article

Histamine: an inhibitor of cytochrome P-450-catalysed drug metabolismLENNARD, M. S; CREWE, H. K; TUCKER, G. T et al.Biochemical pharmacology. 1986, Vol 35, Num 15, pp 2459-2460, issn 0006-2952Article

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamicsLEWIS, R. V; LENNARD, M. S; JACKSON, P. R et al.British journal of clinical pharmacology. 1985, Vol 19, Num 3, pp 329-333, issn 0306-5251Article

Disopyramide elimination in the isolated perfused rat liverLENNARD, M. S; TUCKER, G.T; WOODS, H. F et al.Xenobiotica (London. Print). 1984, Vol 14, Num 11, pp 885-892, issn 0049-8254Article

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranololLENNARD, M. S; JACKSON, P. R; FREESTONE, S et al.British journal of clinical pharmacology. 1984, Vol 17, Num 6, pp 679-685, issn 0306-5251Article